Cochrane review highlights systemic gaps in Alzheimer’s amyloid-focused treatment strategies
Original framing: “STAT+: Cochrane review reignites Alzheimer’s amyloid wars” — STAT News
The original framing omits the role of lifestyle factors, environmental toxins, and chronic inflammation in Alzheimer’s progression. It also fails to incorporate insights from indigenous and holistic health systems that emphasize brain health through diet, community, and mental well-being. Additionally, the voices of patients and caregivers, particularly from low-income and non-Western contexts, are largely absent.
Medium structural omission detected in mainstream coverage.
This narrative is produced by a major U.S.-based science journalism outlet, STAT News, and is likely shaped by its biotech industry readership and funding ecosystem. The framing serves the interests of pharmaceutical companies by reinforcing the amyloid hypothesis as a dominant paradigm, while obscuring alternative models and holistic approaches that may challenge the current profit-driven R&D model.
The Cochrane review provides a meta-analysis of clinical trials, revealing that amyloid-targeting therapies have not consistently improved cognitive outcomes. This calls into question the scientific validity of the amyloid hypothesis as a primary treatment target.
The Cochrane review on Alzheimer’s amyloid-targeting therapies reveals a systemic overreliance on a single-biomarker model that has dominated research for decades.